The quantitation by gas chromatography-chemical ionisation-mass spectrometry of cyclophosphamide, phosphoramide mustard and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy

  • I. Jardine
  • C. Fenselau
  • M. Appler
  • M.-N. Kan
  • R. B. Brundrett
  • M. Colvin

Abstract

Cyclophosphamide, the widely used antitumour drug, is not itself toxic, but must be converted by microsomal metabolism to active metabolites. Despite an early understanding of the requirement for metabolic activation, the drug was used clinically for more than 10 years before the structures of any of its hepatic metabolites were elucidated. When the metabolites were finally isolated and identified, their characterisation rested heavily on mass spectral analysis (Bakke, Feil and Zaylskie, 1971; Colvin, Padgett and Fenselau, 1973; Struck et al., 1971). Subsequently mass spectrometry has been used in conjunction with stable-isotope labels to study the mechanism of alkylation of cytotoxic metabolites (Colvin et al., 1976) and for experiments with metabolic switching (Jarman et al., this volume pp. 85–95). Methodology has also been reported for assaying these cytotoxic metabolites using stable-isotope-labelled internal standards (Jardine et al., 1975, 1976; Jarman et al., 1975). In this report we will review the application of this methodology to assays of cyclophosphamide, phosphoramide mustard and nornitrogen mustard in blood and urine of patients, as well as in decomposition and protein-binding studies.

Keywords

Lithium Chlorine Radioactive Isotope Cyclophosphamide Diol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bagley, C. M. Jr., Botick, F. W. and De Vita, V. T. Jr. (1973). Cancer Res., 33, 226Google Scholar
  2. Bakke, J. E., Feil, V. J. and Zaylskie, R. R. (1971). Agric. Food Chem., 19, 788CrossRefGoogle Scholar
  3. Cohen, J. L., Jao, J. Y. and Jusko, W. J. (1971). Brit. J. Pharmacol., 43, 677CrossRefGoogle Scholar
  4. Colvin, M., Padgett, C. A. and Fenselau, C. (1973). Cancer Res., 33, 915Google Scholar
  5. Colvin, M., Brundrett, R. B., Kan, M. N., Jardine, I. and Fenselau, C. (1976). Cancer Res., 36, 1121Google Scholar
  6. Fenselau, C., Kan, M.-N., Billets, S. and Colvin, M. (1975). Cancer Res., 35, 1453Google Scholar
  7. Jardine, I., Kan, M.-N. N., Fenselau, C., Brundrett, R., Colvin, M., Wood, G., Lau, P.-Y. and Charlton, R. (1975). Proceedings of the Second International Conference on Stable Isotopes (ed. E. R. Klein and P. D. Klein), Oak Brook, Illinois, U.S.A., National Technical Information Service Document CONF-751027, p. 138Google Scholar
  8. Jardine, I., Brundrett, R., Colvin, M. and Fenselau, C. (1976). Cancer Treat. Rep., 60, 403Google Scholar
  9. Jardine, I., Fenselau, C., Appler, M., Kan, M.-N., Brundrett, R. B. and Colvin, M. (1977). Cancer Res. (in press)Google Scholar
  10. Jarman, M., Gilby, E. D., Foster, A. B. and Bondy, D. K. (1975). Clin. Chim. Acta, 58, 61CrossRefGoogle Scholar
  11. Maddock, C. L., Handler, A. H., Friedman, O. M., Foley, G. E. and Farber, S. (1966). Cancer Chemother. Rep., 50, 629Google Scholar
  12. Struck, R. F., Kirk, M. C., Mellett, L. M., El Dareer, S. and Hill, D. L. (1971). Molec. Pharmacol., 7, 519Google Scholar
  13. Takamizawa, W. A., Matsumoto, S., Iwata, T., Tochino, Y., Katagiri, K., Yamaguchi, K. and Shiratori, O. (1975). J. Med. Chem., 18, 376CrossRefGoogle Scholar

Copyright information

© The Contributors 1978

Authors and Affiliations

  • I. Jardine
    • 1
  • C. Fenselau
    • 1
  • M. Appler
    • 1
  • M.-N. Kan
    • 1
  • R. B. Brundrett
    • 1
  • M. Colvin
    • 1
  1. 1.Departments of Pharmacology and Experimental Therapeutics and of MedicineThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations